ace inhibitor + angiotensin receptor blocker + beta blocker

This is a combination therapy consisting of three classes of antihypertensive drugs: - **ACE inhibitors (angiotensin-converting enzyme inhibitors):** These drugs lower blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby relaxing blood vessels and reducing blood pressure. - **Angiotensin receptor blockers (ARBs):** ARBs block the action of angiotensin II at its receptor, preventing vasoconstriction and aldosterone-mediated volume expansion. - **Beta blockers:** These agents reduce heart rate and contractility by blocking beta-adrenergic receptors, leading to decreased cardiac output and lower blood pressure. The rationale for combining these agents is based on their complementary mechanisms targeting different aspects of the renin–angiotensin–aldosterone system (RAAS) and sympathetic nervous system. However, evidence for clinical benefit from triple therapy with all three classes is limited. While dual combinations such as ACE inhibitor plus ARB or ACE inhibitor plus beta blocker are sometimes used in specific cardiovascular conditions like heart failure or resistant hypertension, there is insufficient evidence supporting routine use of all three together. Additionally, combining these medications increases the risk for adverse effects such as hypotension, renal dysfunction, hyperkalemia, and bradycardia[1][2][4].